Compare
Composo vs Galileo
Galileo has built a proprietary 440M-parameter evaluation foundation model (Luna) and sells it into enterprise. Composo takes a different approach: we use frontier LLMs with domain-specific calibration and retrieval-based learning from corrections. Both are reasonable positions. The right choice depends on whether you prefer proprietary infrastructure depth or domain-calibration speed.
Galileo bets on a proprietary evaluation foundation model. Composo bets on calibration and correction-learning on top of frontier models.
At a glance
| Dimension | Composo | Galileo |
|---|---|---|
| Core technology | Domain-calibrated reward model, retrieval-based correction learning | Luna - 440M-parameter proprietary evaluation foundation model |
| Alignment with human experts | 90%+ alignment with human domain experts in most production contexts | Luna outperforms GPT-3.5 by 18% on hallucination detection (vendor claim) |
| Positioning | Quality layer for domain-specific AI in regulated industries | Enterprise "Evaluation Intelligence" platform |
| Notable customers | Healthcare, fintech, legal, enterprise AI teams | Comcast, Twilio, HP, ServiceTitan, six Fortune 50 companies |
| Moat strategy | Failure taxonomy + correction-based learning per deployment | Proprietary foundation model + cost/speed efficiency claims |
| Deployment model | FDE deployment (2 to 4 weeks) with calibration | SaaS self-serve + enterprise tier |
| Commercial stage | Seed, growing | Commercial-stage (834% revenue growth reported in 2024) |
Where Galileo is strong
- Proprietary infrastructure depth. Luna is a real differentiator if you believe evaluation models should be distinct from general-purpose LLMs. Galileo has invested heavily in this direction.
- Cost and speed claims. Galileo reports that Luna achieves a 97% cost reduction and 11× speed improvement over LLM-as-judge on the hallucination detection task.
- Enterprise traction. Named Fortune 50 customers and 834% revenue growth in 2024 suggest the enterprise playbook is working.
- Breadth of evaluation types. Hallucination, toxicity, PII, groundedness, and bespoke metrics all supported out of the box.
- Strong research brand. Galileo's research publications give it credibility with ML-engineering-heavy buyers.
Where Composo is different
- Calibration beats a generic proprietary model. Luna is a generic hallucination model. For a clinical AI, hallucination is not the only failure mode - omitted findings, diagnostic leaps, and dosage errors all matter and are domain-specific. Composo calibrates to those specific failures.
- Frontier-model leverage. Composo uses frontier LLMs (GPT-5, Claude Sonnet) inside its evaluation pipeline. As frontier models improve, Composo's evaluation quality improves with them. Luna is frozen until Galileo retrains it.
- Deployment is the product. A senior engineer deploys, calibrates, and hands over. With Galileo, you configure evaluators yourself.
- Correction learning. Domain experts label edge cases; the evaluation system generalises those corrections. This is a different learning mechanism from Luna's training-time supervision.
- Human-expert alignment as the operational bar. Composo measures success on alignment with human domain experts, not on a single benchmark number. 90%+ alignment in most production contexts is the standard Composo deploys to.
When to pick which
Pick Galileo if
- · You are a Fortune 500 buying a mature, branded enterprise evaluation platform
- · Cost of inference is a dominant concern at very large scale
- · You want a broad set of out-of-the-box metrics (hallucination, toxicity, PII)
- · You prefer a self-serve SaaS model over a deployment engagement
Pick Composo if
- · Your AI is domain-specific and generic hallucination scores miss your real failure modes
- · You want a deployed quality layer calibrated to your failure taxonomy, not a configurable platform
- · You want to ride frontier-model improvements (GPT-5+, Claude 4.x+) through your evaluation layer
- · You are in healthcare, fintech, legal, or another regulated vertical where domain precision matters
Frequently asked questions
Is Galileo's Luna model better than frontier-model based evaluation?
For the specific task of hallucination detection, Galileo reports Luna outperforms GPT-3.5 by 18%. For broader domain-specific evaluation, Composo uses frontier models with criteria ensembling and domain calibration to reach 90%+ alignment with human domain experts in most production contexts. The right answer depends on whether your failure modes are generic (hallucination, toxicity) or domain-specific.
Can I use Galileo and Composo together?
Technically yes, but the overlap is high. Most teams pick one or the other as their primary quality layer. If you already use Galileo and are missing specific domain failure modes, Composo can be added for the targeted use cases.
How does Composo's research compare to Galileo's?
Both invest in original research. Galileo has published on Luna and related hallucination detection work. Composo publishes on practical LLM-as-judge improvement techniques (criteria ensembling, variance-informed calibration, reward modelling) that reach 90%+ alignment with human domain experts without retraining a foundation model - a different methodology reaching a comparable or better production accuracy bar.
Which is faster to deploy?
Galileo is faster to start using (self-serve SaaS). Composo takes 2 to 4 weeks to deploy but arrives calibrated to your specific domain. For a healthcare or financial-services deployment, calibration is usually worth the slower start.
How does pricing compare?
Both are enterprise-tier. Galileo publishes little public pricing; Composo is a deployment contract scoped per customer. Specifics are on a diagnostic call.
See what Composo catches on your own AI.
A clinical-quality failure report on your production AI, delivered in under a week.